In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

Neurology ◽  
1997 ◽  
Vol 49 (3) ◽  
pp. 717-723 ◽  
Author(s):  
N. Turjanski ◽  
A. J. Lees ◽  
D. J. Brooks
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Striatal Dopamine ◽  
In Vivo Studies ◽  
Site Binding

scholarly journals Effect of Harmine against Parkinson’s Disease Protein (PARK7) through Molecular Docking Studies

2021 ◽  
Vol 9 (VI) ◽  
pp. 5479-5485
Author(s):  
Love Kumar
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Molecular Docking ◽  
Neurodegenerative Disorder ◽  
Docking Studies ◽  
In Vivo Studies ◽  
Receptor Protein ◽  
Unknown Etiology

Parkinson’s disease (PD) is a common known neurodegenerative disorder with unknown etiology. It was estimated about 0.3% prevalence in the U.S population and enhance to 4 to 5% in older than 85 years. All studies were depending on the molecular docking where all ligands and protein PARK7 (PDB ID: 2RK3) were interacted by docked process. Some natural compounds was selected such as Harmine, Alloxan, Alpha spinasterol, Myrcene, and Vasicinone and PARK7 (PDB ID: 2RK3) protein. According to the PyRx and SWISS ADME result, Harmine was the only ligand which was showing minimum binding affinity. AutoDock Vina software was used for docking process between ligand (Harmine) and receptor protein PARK7 (PDB ID: 2RK3). The result was visualized under PyMol. Harmine was inhibiting the activity of PARK7 (PDB ID: 2RK3) and it may be used for the treatment of PD in future prospect after its in vitro and in vivo studies.

Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson’s disease: Synthesis, in vitro and in vivo studies

2020 ◽  
Vol 101 ◽  
pp. 103986 ◽  
Author(s):  
Fernanda Rodríguez-Enríquez ◽  
Dolores Viña ◽  
Eugenio Uriarte ◽  
José Angel Fontenla ◽  
Maria J. Matos
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Novel Agents ◽  
In Vivo Studies

scholarly journals Neuroprotective Effects of Lindleyin on Hydrogen Peroxide-Induced Cell Injury and MPTP-Induced Parkinson’s Disease in C57BL/6 Mice

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Jin-Jie Zhang ◽  
Xiao-Rong Shi ◽  
Wen-Wen Lv ◽  
Xiao-Long Zhou ◽  
Ying-Dong Sun ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Hydrogen Peroxide ◽  
Parkinson's Disease ◽  
Cell Injury ◽  
In Vivo Studies ◽  
Antioxidant Enzyme Activities ◽  
Apoptotic Pathway ◽  
Neuroprotective Effects

Oxidative stress (OS) is a crucial factor influencing the development of Parkinson’s disease (PD). Here we first reported that Lindleyin (Lin), one of the major components of rhubarb, possessed neuroprotective effects against H2O2-induced SH-SY5Y cell injury and MPTP-induced PD of C57BL/6 mice. The results showed that Lin can decrease cell death and apoptotic rate induced by H2O2 through inhibiting mitochondrial apoptotic pathway and increasing the activities of SOD, GSH-Px, and CAT as well as decreasing the level of MDA. In addition, in vivo studies showed that oral administration of Lin (5 or 20 mg/kg) showed significant change in motor function deficits, antioxidant enzyme activities, apoptotic pathway, and tyrosine hydroxylase expression. Our results reveal that Lin might be a promising anti-PD agent by reducing OS and apoptosis.

Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model

2012 ◽  
Vol 22 (19) ◽  
pp. 6286-6291 ◽  
Author(s):  
Abhisek Banerjee ◽  
Sandip Patil ◽  
Mahesh Y. Pawar ◽  
Srinivas Gullapalli ◽  
Praveen K. Gupta ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Model ◽  
In Vivo Studies

scholarly journals The Multiple Roles of Sphingomyelin in Parkinson’s Disease

Biomolecules ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1311
Author(s):  
Paola Signorelli ◽  
Carmela Conte ◽  
Elisabetta Albi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nerve Impulse ◽  
In Vivo Studies ◽  
Metabolizing Enzymes ◽  
Molecular Alterations ◽  
Receptor Localization ◽  
Genetic Risks

Advances over the past decade have improved our understanding of the role of sphingolipid in the onset and progression of Parkinson’s disease. Much attention has been paid to ceramide derived molecules, especially glucocerebroside, and little on sphingomyelin, a critical molecule for brain physiopathology. Sphingomyelin has been proposed to be involved in PD due to its presence in the myelin sheath and for its role in nerve impulse transmission, in presynaptic plasticity, and in neurotransmitter receptor localization. The analysis of sphingomyelin-metabolizing enzymes, the development of specific inhibitors, and advanced mass spectrometry have all provided insight into the signaling mechanisms of sphingomyelin and its implications in Parkinson’s disease. This review describes in vitro and in vivo studies with often conflicting results. We focus on the synthesis and degradation enzymes of sphingomyelin, highlighting the genetic risks and the molecular alterations associated with Parkinson’s disease.

scholarly journals Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson’s disease

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Uzma Saleem ◽  
Zohaib Raza ◽  
Fareeha Anwar ◽  
Zunera Chaudary ◽  
Bashir Ahmad
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Experimental Model ◽  
Mechanism Of Action ◽  
System Level ◽  
In Vivo Studies ◽  
Substantia Nigra Pars Compacta ◽  
Systems Pharmacology ◽  
Albizia Lebbeck

Abstract Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in substantia nigra pars compacta and clinically manifested mainly with motor dysfunctions. Plants are rich source of medicinally important bioactive compounds and inhabitants of underdeveloped countries used plants for treatment of various ailments. Albizia lebbeck has been reported to possess antioxidant and neuroprotective properties that suggest the evaluation of its traditional therapeutic potential in neurodegenerative diseases. The aim of present study was to validate the traditional use of Albizia lebbeck (L.) and delineate its mechanism of action in PD. The systems pharmacology approach was employed to explain the Albizia lebbeck (L.) mechanism of action in PD. Methods The haloperidol-induced catalepsy was adopted as experimental model of PD for in-vivo studies in wistar albino rats. The systems pharmacology approach was employed to explain the Albizia lebbeck (L.) mechanism of action in PD. Results In-vivo studies revealed that Albizia lebbeck improved the motor functions and endurance as demonstrated in behavioral studies which were further supported by the rescue of endogenous antioxidant defense and reversal of ultrastructural damages in histological studies. System pharmacology approach identified 25 drug like compounds interacting with 132 targets in a bipartite graph that revealed the synergistic mechanism of action at system level. Kaemferol, phytosterol and okanin were found to be the important compounds nodes with prominent target nodes of TDP1 and MAPT. Conclusion The therapeutic efficiency of Albizia lebbeck in PD was effectively delineated in our experimental and systems pharmacology approach. Moreover, this approach further facilitates the drug discovery from Albizia lebbeck for PD.

scholarly journals rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies

2019 ◽  
Vol 216 (3) ◽  
pp. 539-555 ◽  
Author(s):  
Cara L. Croft ◽  
Pedro E. Cruz ◽  
Daniel H. Ryu ◽  
Carolina Ceballos-Diaz ◽  
Kevin H. Strang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Transgene Expression ◽  
Brain Slice ◽  
Ex Vivo ◽  
Three Dimensional ◽  
Cost Effective ◽  
In Vivo Studies ◽  
Slice Culture

It has been challenging to produce ex vivo models of the inclusion pathologies that are hallmark pathologies of many neurodegenerative diseases. Using three-dimensional mouse brain slice cultures (BSCs), we have developed a paradigm that rapidly and robustly recapitulates mature neurofibrillary inclusion and Lewy body formation found in Alzheimer’s and Parkinson’s disease, respectively. This was achieved by transducing the BSCs with recombinant adeno-associated viruses (rAAVs) that express α-synuclein or variants of tau. Notably, the tauopathy BSC model enables screening of small molecule therapeutics and tracking of neurodegeneration. More generally, the rAAV BSC “toolkit” enables efficient transduction and transgene expression from neurons, microglia, astrocytes, and oligodendrocytes, alone or in combination, with transgene expression lasting for many months. These rAAV-based BSC models provide a cost-effective and facile alternative to in vivo studies, and in the future can become a widely adopted methodology to explore physiological and pathological mechanisms related to brain function and dysfunction.

scholarly journals Molecular Docking Studies of Secondary Metabolites against Sequestosome-1 to Treat Parkinson Disease

2021 ◽  
Vol 9 (VI) ◽  
pp. 4456-4464
Author(s):  
Neeraj .
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rosmarinic Acid ◽  
The Body ◽  
In Vivo Studies ◽  
Axial Tomography ◽  
Low Level ◽  
Sequestosome 1

Parkinson's disease (PD) is one of the major progressive neurological disorders. It occurs due to a low level of a chemical substance in the brain known as Dopamine, which controls the muscle movements of the body. In many cases, PD occurs due to a low level of dopamine. PD generally appears in persons between the ages of 50 & 60. Some common symptoms of Parkinson's are slow movements, tremors, change in voice, depression, anxiety, hallucinations, psychosis, etc. Diagnosis of PD is done by CAT (Computerized Axial Tomography) scan or MRI (Magnetic Resonance Imaging, and DAT (Dopamine Transporter) scan. No specific cure for PD but Medication, Surgery, Adequate rest, exercise, and a balanced diet, and Several different drugs may help to relieve Parkinson's Disease (PD). According to the in silico study, we found that Rosmarinic Acid (RA) was the compound, which may inhibit the activities of Sequestosome-1. After in vitro and in vivo studies, Rosmarinic Acid may be an effective drug to control Parkinson's disease (PD).

Sign in / Sign up

Export Citation Format

Share Document